CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 52 enrolled
Drug / intervention
TACE plus autologous Tcm immunotherapy +1 morecombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03575806
NCT03575806Phase 2Completed
CompareCT.gov

A Single-center, Open-label, Exploratory Trial of Autologous Immunotherapy for Hepatocellular Carcinoma (HCC) With Microvascular Invasion (MVI) After Radical Resection

Cancer Institute and Hospital, Chinese Academy of Medical Sciences·interventional·Posted Jul 3, 2018·Updated Jun 11, 2020

In Brief

A Phase 2 clinical trial evaluating TACE plus autologous Tcm immunotherapy and TACE for Hepatocellular Carcinoma and Malignant Neoplasm. Completed, enrolled 52 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the efficacy and safety of combining autologous Tcm immunotherapy and TACE in HCC patients with MVI after radical resection. Patients will be assigned either to the experimental arm to receive autologous Tcm immunotherapy and TACE or to the active comparator (TACE alone).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma, Malignant Neoplasm
CountriesChina
CollaboratorsNewish Technology (Beijing) Co., Ltd.

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 3, 2018
Enrollment StartJan 9, 2017
Primary CompletionOct 31, 2019
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 8.0 years ago

Interventions

TACE plus autologous Tcm immunotherapycombination

TACE:transcatheter arterial chemoembolization. Autologous Tcm immunotherapy: to collect patient's own immune cells and then given back to the patient after amplified in vitro.

TACEprocedure

TACE:transcatheter arterial chemoembolization.